KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema.

Andrea Bauer, Lyn Guenther, Richard Woolf, Eydna Didriksen Apol, Douglas Maslin, Nanna Nyholm, Henrik Thoning, Marie Louise Schuttelaar

Contact Dermatitis 95(1) 91-99

PMID41775339
PMCIDPMC13238450
DOI10.1111/cod.70114
发表日期2026-03-03
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Chronic Hand Eczema (CHE) is a multifactorial, fluctuating inflammatory disease of the hands and wrists that negatively impacts patients' health-related quality of life (HRQoL). OBJECTIVES: To assess the effects of delgocitinib cream versus cream vehicle on HRQoL. METHODS: DELTA 1 and DELTA 2 were phase 3 trials of identical design in which adults with moderate to severe CHE were randomised (2:1) to double-blind treatment with delgocitinib cream 20 mg/g or cream vehicle twice daily for 16 weeks. Data were pooled from both trials and changes in EQ-5D, Dermatology Life Quality Index (DLQI), and Hand Eczema Impact Scale (HEIS), including the HEIS Proximal Daily Activity Limitations (PDAL) and HEIS Embarrassment (Emb) subsets, were compared. RESULTS: Across the two trials, 639 patients were randomised to delgocitinib cream and 321 to cream vehicle. Delgocitinib cream resulted in significantly greater improvement in EQ-5D, DLQI, HEIS, HEIS PDAL, and HEIS Emb compared with cream vehicle at week 16 (all p < 0.001). More patients achieved clinically meaningful improvement from baseline in patient-reported outcomes at week 16 (all p < 0.001), and the mean time spent in an improved HRQoL state increased with delgocitinib cream. CONCLUSIONS: Delgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. CLINICAL TRIAL ID: DELTA 1 (NCT04871711) and DELTA 2 (NCT04872101).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Changes from baseline to week 16 in (A) EQ‐5D, (B) DLQI, (C) HEIS, (D) HEIS PDAL, and (E) HEIS Emb in patients treated with delgocitinib cream or cream vehicle. * p < 0.05; ** p ≤ 0.001. Dotted line represents the minimum clinically important difference from baseline (EQ‐5D, not applicable). DLQI, Dermatology Life Quality Index; Emb, Embarrassment; EQ‐5D, EuroQol 5‐dimension HEIS; Hand Eczema Impact Scale; PDAL, Proximal Daily Activity Limitations.
非 KM Figure
FIGURE 2Estimated treatment differences in individual items/domains of EQ‐5D, DLQI and HEIS (including HEIS PDAL and HEIS Emb). (A) EQ‐5D (difference in % of patients reporting ‘no problems’ for each item). (B) DLQI (difference in % of patients reporting ‘not at all’ in response to each question). (C) HEIS (difference in % of patients reporting ‘not at all’ in response to each question).
非 KM Figure
FIGURE 3Proportions of patients achieving a minimum clinically important improvement in DLQI, HEIS, HEIS PDAL, and HEIS Emb after 16 weeks of treatment with delgocitinib cream or cream vehicle. DLQI, Dermatology Life Quality Index; Emb, Embarrassment; HEIS; Hand Eczema Impact Scale; PDAL, Proximal Daily Activity Limitations.
非 KM Figure
FIGURE 4Improvement in EQ VAS, DLQI, HEIS, HEIS PDAL and HEIS Emb from baseline to week 16 in a patient with CHE (irritant, allergic, and atopic subtypes with a history of treatment with topical corticosteroids and topical calcineurin inhibitors) treated with delgocitinib cream. DLQI, Dermatology Life Quality Index; Emb, Embarrassment; HECSI, hand eczema severity index; HEIS; Hand Eczema Impact Scale HESD, hand eczema symptom diary; IGA‐CHE, Investigator's Global Assessment‐Chronic Hand Eczema; PDAL, Proximal Daily Activity Limitations; VAS, visual analogue scale.
非 KM Figure